share_log

Concerns Surrounding Hangzhou Coco Healthcare ProductsLtd's (SZSE:301009) Performance

Concerns Surrounding Hangzhou Coco Healthcare ProductsLtd's (SZSE:301009) Performance

杭州可可健康产品有限公司(SZSE:301009)绩效相关的关注事项
Simply Wall St ·  11/02 20:47

Hangzhou Coco Healthcare Products Co.,Ltd.'s (SZSE:301009) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

杭州可可保健制品有限公司(SZSE:301009)最近的强劲收益并没有对股价产生太大影响。我们认为股东们注意到了一些超出法定利润数字的令人担忧的因素。

big
SZSE:301009 Earnings and Revenue History November 3rd 2024
SZSE:301009 盈利和营业收入历史数据 2024年11月3日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Hangzhou Coco Healthcare ProductsLtd's profit received a boost of CN¥1.9m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Hangzhou Coco Healthcare ProductsLtd had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

重要的是,我们的数据显示,杭州可可保健制品有限公司的利润在过去一年中由于不寻常项目的增加而获得了190万元人民币的提升。虽然我们喜欢看到利润增长,但当不寻常项目做出重大贡献时,我们往往会更加谨慎。当我们对成千上万家上市公司的数据进行分析时,我们发现某一年来自不寻常项目的提升在下一年通常不会重复。这并不奇怪,考虑到其名称。与2024年9月相比,杭州可可保健制品有限公司的不寻常项目对其利润贡献相当显著。其他条件相同的情况下,这可能会导致法定利润不再是基础盈利能力的有效指引。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Hangzhou Coco Healthcare ProductsLtd's Profit Performance

我们对杭州可可健康保健产品有限公司的利润表现看法

As previously mentioned, Hangzhou Coco Healthcare ProductsLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Hangzhou Coco Healthcare ProductsLtd's underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 1 warning sign for Hangzhou Coco Healthcare ProductsLtd you should be aware of.

正如先前提到的,杭州可可保健产品有限公司由于飞凡项目的大幅提升,在这一特殊项目的帮助下,公司的法定收入可能不会无限期存在,因此,其财务报表收益可能不是判断其潜在盈利能力的良好指标。因此,我们认为杭州可可保健产品有限公司的潜在收益能力可能低于其法定利润。好消息是,公司今年实现了盈利,而去年则亏损。本文的目的是评估我们能否依靠财务报表收益来反映公司的潜在,但还有许多因素需考虑。请牢记,在分析股票时,注意其中涉及的风险是值得的。例如,我们发现了杭州可可保健产品有限公司的一个警示信号,您应该注意。

This note has only looked at a single factor that sheds light on the nature of Hangzhou Coco Healthcare ProductsLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

这篇笔记只研究了一个揭示杭州可可保健产品有限公司利润性质的因素。但如果您能将注意力集中在细枝末节上,则还有更多发现。例如,许多人认为高净资产收益率是有利的商业经济指标,而其他人喜欢“追随资金”并寻找内部人员正在买入的股票。尽管这可能需要您进行一些研究,但您可能会发现这些拥有高净资产收益率的公司的免费合集,或者具有显著内部持股的股票列表非常有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发